The cognitive safety of antimuscarinics in the treatment of overactive bladder

References

• Haylen BT, de Ridder D, Freeman RM, et al., An International urogynaecological association (IUGA)/International continence society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 21(1): 5–26. 2010.
   PubMed Web of Science ®Google Scholar
• Stewart WF, Corey R, Herzog AR, et al. Prevalence of overactive bladder in women: results from the NOBLE program. Int Urogynaecol J. 2001;12(3):S66.
   Google Scholar
• Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87(9):760–766.
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Hunskaar S, et al. Population –based survey of urinary incontinence, overactive bladder and other lower urinary tract symptoms in five countries; results of the EPIC study. Eur Urol. 2006;50(6):1306–1314.
   PubMed Web of Science ®Google Scholar
• Irwin DE, Mungapen L, Milsom I, et al. The economic impact of overactive bladder syndrome in six Western countries. BJU Int. 2009;103(2):202–209.
   PubMed Web of Science ®Google Scholar
• Sexton CC, Coyne KS, Vats V, et al. Impact of overactive bladder on work productivity in the United States: results from EpiLUTS. Am J Manag Care. 2009;15(4 Suppl):S98–S107.
   PubMedGoogle Scholar
• Liberman JN, Hunt TL, Stewart WF, et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a US community-based survey. Urology. 2001 Jun 1;57(6):1044–1050.
   PubMed Web of Science ®Google Scholar
• Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health related quality of life in overactive bladder: results from a national community survey. Value Health. 2004 Jul;7(4):455–463.
   PubMed Web of Science ®Google Scholar
• Hashim H, Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity? J Urol. 2006;175(1):191–195.
   PubMed Web of Science ®Google Scholar
• Salvatore S, Delancey J, Igawa Y, et al. Pathophysiology of urinary incontinence, faecal incontinence and pelvic organ prolapse. Abrams P, Cardozo L, Wagg A, et al. editors, Incontinence 6th. Bristol UK: ICI-ICS. International Continence Society; 2017.p. 361–495. ISBN: 978-0956960733.
   Google Scholar
• KE A. The overactive bladder: pharmacologic basis of drug treatment. Urology. 1997;50(6):74–89.
   PubMedGoogle Scholar
• Chancellor MB, Staskin DR, Kay GG, et al. Blood–brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drugs Aging. 2012;29(4):259–273.
   PubMed Web of Science ®Google Scholar
• Hedge SS, Chopin A, Bonhaus D, et al. Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol. 1997;120(8):1409.
   PubMed Web of Science ®Google Scholar
• Fetscher C, Fleichman M, Schmidt M, et al. M (3) muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol. 2002;136(5):641–643.
   PubMed Web of Science ®Google Scholar
• Andersson KE, Cardozo L, Cruz F, et al. Pharmacological treatment of urinary incontinence. Abrams P, Cardozo L, Wagg A, et al. editors, Incontinence 6th. Bristol UK: ICI-ICS. International Continence Society; 2017.p. 805–957. ISBN: 978-0956960733.
   Google Scholar
• Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543–562.
   PubMed Web of Science ®Google Scholar
• Kay GG, Granville LJ. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly. Clin Ther. 2005;27(1):127–138.
   PubMed Web of Science ®Google Scholar
• Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry. 2001;62(Suppl 21):11–14.
   PubMed Web of Science ®Google Scholar
• Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011;59(8):1477–1483.
   PubMed Web of Science ®Google Scholar
• Salom IL, Davis K. Prescribing for older patients: how to avoid toxic drug reactions. Geriatrics. 1995;50(10):37–40.
   PubMed Web of Science ®Google Scholar
• Wagg A. Treating overactive bladder in the elderly. Can Urol Assoc J. 2011 Oct;5(5 Suppl 2):S149 z
   Google Scholar
• Chancellor M, Boone T. Anticholinergics for overactive bladder therapy: central nervous system effects. CNS Neurosci Ther. 2012 Feb;18(2):167–174.
   PubMed Web of Science ®Google Scholar
• Hustveit O. Interaction between opioid and muscarinic receptors in the guineapig ileum preparation: a mathematical model. Toxicol Pharmacol. 1996;78(3):167–173.
   PubMedGoogle Scholar
• Johnell K, Fastbom J. Concurrent use of anticholinergic drugs and cholinesterase inhibitors. Drugs Aging. 2008 Oct 1;25(10):871–877.
   PubMed Web of Science ®Google Scholar
• Shi S, Klotz U. Age-related changes in pharmacokinetics. Curr Drug Metab. 2011 Sep 1;12(7):601–610.
   PubMed Web of Science ®Google Scholar
• Callegari E, Malhotra B, Bungay PJ, et al. A comprehensive nonclinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol. 2011 Mar 11;72(2):235–246.
   PubMed Web of Science ®Google Scholar
• Ali S, Peterson GM, Bereznicki LR, et al. Association between anticholinergic drug burden and mortality in older people: a systematic review. Eur J Clin Pharmacol. 2020 Mar;76(3):319–35
   PubMed Web of Science ®Google Scholar
• Araklitis G, Thiagamoorthy G, Hunter J, et al. Anticholinergic prescription: are healthcare professionals the real burden? Int Urogynecol J. 2017 Aug 1;28(8):1249–1256.
   PubMed Web of Science ®Google Scholar
• Villalba-Moreno AM, Alfaro-Lara ER, Pérez-Guerrero MC, et al. Systematic review on the use of anticholinergic scales in poly pathological patients. Arch Gerontol Geriatr. 2016;62:1–8.
   PubMed Web of Science ®Google Scholar
• Lozano-Ortega G, Johnston KM, Cheung A, et al. A review of published anticholinergic scales and measures and their applicability in database analyses. Arch Gerontol Geriatr. 2020 Mar 1;87:103885.
   PubMed Web of Science ®Google Scholar
• Kersten H, Wyller TB. Anticholinergic drug burden in older people’s brain–How well is it measured? Basic Clin Pharmacol Toxicol. 2014;114(2):151–159.
   PubMed Web of Science ®Google Scholar
• Oelke M, Becher K, Castro-Diaz D, et al. Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014). Age Ageing. 2015 Sep 1;44(5):745–755.
   PubMed Web of Science ®Google Scholar
• American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227–2246.
   PubMed Web of Science ®Google Scholar
• O’Mahony D, O’Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015 Mar 1;44(2):213–218.
   PubMed Web of Science ®Google Scholar
• agingbraincare.org [Internet]. Regenstrief Institute, Inc; [cited 2012]. Available from: http://ww7.agingbraincare.org/
   Google Scholar
• Campbell NL, Boustani MA, Lane KA, et al. Use of anticholinergics and the risk of cognitive impairment in an African American population. Neurology. 2010 Jul 13;75(2):152–159.
   PubMed Web of Science ®Google Scholar
• AE R, Kuo YM, Potter PE, et al. Cortical cholinergic denervation elicits vascular Aβ deposition. Ann N Y Acad Sci. 2000 Apr;903(1):366–373.
   PubMedGoogle Scholar
• Perry EK, Kilford L, Lees AJ, et al. Increased Alzheimer pathology in Parkinson’s disease related to antimuscarinic drugs. Ann Neurol. 2003;54(2):235–238.
   PubMed Web of Science ®Google Scholar
• Risacher SL, McDonald BC, Tallman EF, et al. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol. 2016 Jun 1;73(6):721–732.
   PubMed Web of Science ®Google Scholar
• Fox C, Smith T, Maidment I, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing. 2014 Sep 1;43(5):604–615.
   PubMed Web of Science ®Google Scholar
• Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015 Mar 1;175(3):401–407.
   PubMed Web of Science ®Google Scholar
• Richardson K, Fox C, Maidment I, et al. Anticholinergic drugs and risk of dementia: case-control study. bmj. 2018 Apr 25;361:k1315.
   PubMedGoogle Scholar
• Campbell NL, Lane KA, Gao S, et al. Anticholinergics influence transition from normal cognition to mild cognitive impairment in older adults in primary care. Pharmacother J Human Pharmacol Drug Ther. 2018 May;38(5):511–519.
   Google Scholar
• Wang YC, Chen YL, Huang CC, et al. Cumulative use of therapeutic bladder anticholinergics and the risk of dementia in patients with lower urinary tract symptoms: a nationwide 12-year cohort study. BMC Geriatr. 2019 Dec;19(1):1–9.
   PubMed Web of Science ®Google Scholar
• Bishara D, Perera G, Harwood D, et al. The anticholinergic effect on cognition (AEC) scale—Associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. Int J Geriatr Psychiatry. 2020 May 11;35(9):1069–1077.
   PubMed Web of Science ®Google Scholar
• Lozano-Ortega, G., Schermer, C.R., Walker, D.R. et al. Fall/Fracture-Related Healthcare Costs and Their Association with Cumulative Anticholinergic Burden in People with Overactive Bladder. PharmacoEconomics Open (2020).https://doi.org/https://doi.org/10.1007/s41669-020-0021500215–w
   Google Scholar
• Office for National Statistics. Overview of the UK Population: November 2018. Open Government Licence; 2018.
   Google Scholar
• Brookmeyer R, Johnson E, Ziegler-Graham K, et al. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement. 2007 Jul 1;3(3):186–191.
   PubMed Web of Science ®Google Scholar
• Cantarero-Prieto D, Leon PL, Blazquez-Fernandez C, et al. The economic cost of dementia: A systematic review. Dementia. 2019 Mar;25:1471301219837776.
   Google Scholar
• Maidment I, Grossi C, Richardson K, et al. Increasing prevalence of anticholinergic medication use in older people in England over 20 years: cognitive Function and Ageing Study I and II. (not yet published). 2020. p19. Located at: https://assets.researchsquare.com/files/rs-8515/v3/c6bd2638-efc3-4bac-bc81-55c8a13947bb.pdf
   Google Scholar
• National Institute for Health and Care Excellence (UK). Urinary incontinence and pelvic organ prolapse in women: management.NICE Guideline [NG123]. 2019.
   Google Scholar
• Wagg A. Anticholinergics for overactive bladder in frail and medically complex older people: the case for. Drugs Aging. 2018 Sep 1;35(9):777–780.
   PubMed Web of Science ®Google Scholar
• bladderandbowel.org/ [Internet]. United Kingdom; [cited 2020]. Available from:https://www.bladderandbowel.org/help-information/free-radar-key-home-delivery-service/
   Google Scholar
• Auwad W, Steggles P, Bombieri L, et al. Moderate weight loss in obese women with urinary incontinence: a prospective longitudinal study. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(9):1251–1259.
   PubMed Web of Science ®Google Scholar
• Madhu C, Enki D, Drake MJ, et al. The functional effects of cigarette smoking in women on the lower urinary tract. Urol Int. 2015;95(4):478–482.
   PubMed Web of Science ®Google Scholar
• Hashim H, Abrams P. How should patients with an overactive bladder manipulate their fluid intake? BJU Int. 2008;102(1):62–66.
   PubMed Web of Science ®Google Scholar
• Hashim H, Al Mousa R. Management of fluid intake in patients with overactive bladder. Curr Urol Rep. 2009;10(6):428–433.
   PubMedGoogle Scholar
• Jura YH, Townsend MK, Curhan GC, et al. Caffeine intake, and the risk of stress, urgency and mixed urinary incontinence. J Urol. 2011;185(5):1775–1780.
   PubMed Web of Science ®Google Scholar
• Echeverri D, Montes FR, Cabrera M, et al. Caffeine’s vascular mechanisms of action. Int J Vasc Med. 2010;2010:834060.
   PubMedGoogle Scholar
• Ribeiro CM, Miguel EM, Silva Jdos S, et al. Application of a nanostructured platform and imprinted sol gel film for determination of chlorogenic acid in food samples. Talanta. 2016;156–157:119–125.
   PubMed Web of Science ®Google Scholar
• Dumoulin C, Adewuyi T, Booth J, et al. Adult conservative management. Abrams P, Cardozo L, Wagg A, et al. editors, Incontinence 6th ISBN: 978-0956960733. Bristol UK: ICI-ICS. International Continence Society; 2017. p. 1443–1628.
   Google Scholar
• Batra SC, Iosif LS. Progesterone receptors in the female urinary tract. J Urol. 1987;138(5):130–134.
   PubMed Web of Science ®Google Scholar
• Iosif C, Bekassy Z. Prevalence of genitourinary symptoms in the late menopause. Acta Obstet Gynaecol Scan. 1984;63(3):257–260. .
   PubMed Web of Science ®Google Scholar
• Cardozo LD, Rekers H, Tapp A, et al. Oestriol in the treatment of post- menopausal urgency: a multicenter study. Maturitas. 1993;18(1):47–53.
   PubMedGoogle Scholar
• Cody JD, Jacobs ML, Richardson K, et al. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev. 2012;10:CD001405.
   PubMedGoogle Scholar
• Cardozo L, Lose G, McClish D, et al. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstet Gynecol Scand. 2004 Oct 1;83(10):892–897.
   PubMed Web of Science ®Google Scholar
• Tseng LH, Wang AC, Chang YL, et al. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome. Neurourol Urodyn. 2009;28(1):47–51.
   PubMed Web of Science ®Google Scholar
• Chughtai B, Forde JC, Buck J, et al. The concomitant use of fesoterodine and topical vaginal oestrogen in the management of overactive bladder and sexual dysfunction in post menopausal women. Post Reprod Health. 2016;22(1):34–40.
   PubMedGoogle Scholar
• Jiang F, Zhu L, Xu T, et al. Efficacy and safety of solifenacin succinate tablets versus solifenacin succinate tablets with local oestrogen for the treatment of overactive bladder in postmenopausal women – a multicentre, randomised, open label, controlled comparison study. Menopause. 2016;23(4):451–457.
   PubMed Web of Science ®Google Scholar
• Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract. 2010 Aug;64(9):1294–1300.
   PubMed Web of Science ®Google Scholar
• Staskin DR, Harnett MD. Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Curr Urol Rep. 2004 Nov 1;5(6):423–426.
   PubMedGoogle Scholar
• Pietzko A, Dimpfel W, Schwantes U, et al. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol. 1994 Nov 1;47(4):337–343.
   PubMed Web of Science ®Google Scholar
• Geller EJ, Crane AK, Wells EC, et al. Effect of anticholinergic use for the treatment of overactive bladder on cognitive function in postmenopausal women. Clin Drug Investig. 2012 Oct 1;32(10):697–705.
   PubMed Web of Science ®Google Scholar
• Geller EJ, Dumond JB, Bowling JM, et al. Effect of trospium chloride on cognitive function in women aged 50 and older: a randomized trial. Female Pelvic Med Reconstr Surg. 2017 Mar 1;23(2):118–123.
   PubMed Web of Science ®Google Scholar
• Woodford HJ. Anticholinergic drugs for overactive bladder in frail older patients: the case against. Drugs Aging. 2018 Sep 1;35(9):773–776.
   PubMed Web of Science ®Google Scholar
• Samuelsson E, Odeberg J, Stenzelius K, et al. Effect of pharmacological treatment for urinary incontinence in the elderly and frail elderly: a systematic review. Geriatr Gerontol Int. 2015 May;15(5):521–534.
   PubMed Web of Science ®Google Scholar
• Wagg A, Khullar V, Michel MC, et al. Long‐term safety, tolerability and efficacy of flexible‐dose fesoterodine in elderly patients with overactive bladder: open‐label extension of the SOFIA trial. Neurourol Urodyn. 2014 Jan;33(1):106–114.
   PubMed Web of Science ®Google Scholar
• DuBeau CE, Kraus SR, Griebling TL, et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. J Urol. 2014 Feb;191(2):395–404.
   PubMed Web of Science ®Google Scholar
• Wagg A, Arumi D, Herschorn S, et al. A pooled analysis of the efficacy of fesoterodine for the treatment of overactive bladder, and the relationship between safety, co-morbidity and polypharmacy in patients aged 65 years or older. Age Ageing. 2017 Jul 1;46(4):620–626.
   PubMed Web of Science ®Google Scholar
• Wesnes KA, Edgar C, Tretter RN, et al. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opin Drug Saf. 2009 Nov 1;8(6):615–626.
   PubMed Web of Science ®Google Scholar
• Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol. 2006 Aug 1;50(2):317–326.
   PubMed Web of Science ®Google Scholar
• Oelke M, Murgas S, Schneider T, et al. Influence of propiverine ER 30 mg once daily on cognitive function in elderly female and male patients with overactive bladder: a non-interventional study to assess real life data. Neurourol Urodyn. 2013 Aug 1;32(6):800–802.
   Web of Science ®Google Scholar
• Kay G, Kardiasmenos K, Crook T. Differential effects of the antimuscarinic agents tolterodine tartrate ER and oxybutynin chloride ER on recent memory in older subjects. Proc Int Continence Soc. 2006 Nov 27;25(6):P087.
   Google Scholar
• Iyer S, Lozo S, Botros C, et al. Cognitive changes in women starting anticholinergic medications for overactive bladder: a prospective study. Int Urogynecol J. 2019 Dec;7:1–8.
   Google Scholar
• Wagg A, Nitti VW, Kelleher C, et al. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics. Curr Med Res Opin. 2016 Apr 2;32(4):621–638.
   PubMed Web of Science ®Google Scholar
• Wagg A, Staskin D, Engel E, et al. Efficacy, safety, and tolerability of mirabegron in patients aged≥ 65 yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR). Eur Urol. 2020 Feb 1;77(2):211–220.
   PubMed Web of Science ®Google Scholar
• Griebling TL, Campbell NL, Mangel J, et al. Effect of mirabegron on cognitive function in elderly patients with overactive bladder: moCA results from a phase 4 randomized, placebo-controlled study (PILLAR). BMC Geriatr. 2020 Dec;20(1):1.
   Web of Science ®Google Scholar
• Gibson W, MacDiarmid S, Huang M, et al. Treating overactive bladder in older patients with a combination of mirabegron and solifenacin: a prespecified analysis from the BESIDE study. Eur Urol Focus. 2017 Dec 1;3(6):629–638.
   PubMedGoogle Scholar
• Bartley J, Gilleran J, Peters K. Neuromodulation for overactive bladder. Nat Rev Urol. 2013 Sep;10(9):513.
   PubMed Web of Science ®Google Scholar
• Palmer C, Farhan B, Nguyen N, et al. Clinical outcomes of percutaneous tibial nerve stimulation in elderly patients with overactive bladder. Arab J Urol. 2019 Jan 2;17(1):10–13.
   PubMed Web of Science ®Google Scholar
• Tutolo M, Ammirati E, Heesakkers J, et al. Efficacy and safety of sacral and percutaneous tibial neuromodulation in non-neurogenic lower urinary tract dysfunction and chronic pelvic pain: a systematic review of the literature. Eur Urol. 2018 Mar 1;73(3):406–418.
   PubMed Web of Science ®Google Scholar
• Amundsen CL, Webster GD. Sacral neuromodulation in an older, urge-incontinent population. Am J Obstet Gynecol. 2002 Dec 1;187(6):1462–1465.
   PubMed Web of Science ®Google Scholar
• White WM, Mobley III JD, Doggweiler R, et al. Sacral nerve stimulation for refractory overactive bladder in the elderly population. J Urol. 2009 Oct 1;182(4):1449–1452.
   PubMed Web of Science ®Google Scholar
• Faris AE, Gill BC, Pizarro-Berdichevsky J, et al. Impact of age and comorbidities on use of sacral neuromodulation. J Urol. 2017 Jul 1;198(1):161–166.
   PubMed Web of Science ®Google Scholar
• Cui Y, Zhou X, Zong H, et al. The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: A systematic review and meta-analysis. Neurourol Urodyn. 2015 Jun;34(5):413–419.
   PubMed Web of Science ®Google Scholar
• Miotla P, Cartwright R, Skorupska K, et al. Urinary retention in female OAB after intravesical Botox injection: who is really at risk? Int Urogynecol J. 2017 Jun 1;28(6):845–850.
   PubMed Web of Science ®Google Scholar
• Perino A, Cucinella G, Gugliotta G, et al. Is vaginal fractional CO. Eur Rev Med Pharmacol Sci. 2016;20(12):2491–2497.
   PubMed Web of Science ®Google Scholar
• Lin YH, Hsieh WC, Huang L, et al. Effect of non-ablative laser treatment on overactive bladder symptoms, urinary incontinence and sexual function in women with urodynamic stress incontinence. Taiwanese J Obstetrics Gynecol. 2017 Dec 1; 56(6):815–820.
   PubMed Web of Science ®Google Scholar